Company update
Buy
Buy

Siemens Healthineers: Weak Q3-22 results, optimistic outlook

Overall core results got hit by lower COVID-19 test demand and supply-chain interruptions. Buy rating confirmed.

03. August 2022
Analyst:
Marcello MusioHead of Equity & Bond Selectionmarcello.musio@vpbank.com

«Dieser Inhalt ist nur auf Englisch verfügbar – This content is available in English only»

Report

  • Q3-22 revenues of EUR 5.2bn inline with expectations
  • Q3-22 gross profit of EUR 1.87bn below expectations (EUR 2bn)
  • Q3-22 EBITDA of EUR 938mn below expectations (EUR 983mn)
  • Q3-22 adjusted operating income of EUR 765 clear below expectations (EUR 841mn)
  • Q3-22 operating margin of 11.45% below expectations (12.4%)
  • Q3-22 free cashflow of EUR 478mn below expectations (EUR 619mn)
  • Adjusted diluted EPS of EUR 0.43 below expectations (EUR 0.49)

Valuation

Siemens Healthineers currently trades at 20.9x P/E 23E, below its 5-year historical average of 22x and above the MSCI Europe Health Care Index (16.1x). On an EV/EBITDA basis, the stock is trading at 15.1x, above its 5-year average of 13.9x and above the MSCI Europe Health Care Index (11.8x).                            

Conclusion

Siemens Healthineers experienced stronger headwinds than anticipated. Supply-chain disruptions and several lockdowns in China weighted on results from different angles. The company expects part of missed sales to get executed during next quarters and hence sticks to its given guidance. As well, necessary price adjustments to follow cost pressures will last throughout the next 18 months. Apart from pandemic related challenges and a weaker economic environment, overall operations had been solid.

We reiterate our buy recommendation.

Management Outlook

Siemens Healthineers reiterated its FY-22 guidance for comparable revenue growth of around 7.5% and adjusted basic earnings of EUR ~2.35 per share at group level.

Financials

Fiscal year 2022* Fiscal year 2023* Fiscal year 2024*
Revenue in mn 21,057 21,684 23,085
Revenue growth (%) 17.9 3.0 6.5
Net Income in mn 2,546 2,667 3,018
Adjusted EPS 2.27 2.37 2.69
Profit margin (%) 12.1 12.3 13.1
Return on equity (%) 14.6 14.3 15.3
P/E ratio (x) 21.9 20.9 18.4
P/S ratio (x) 2.7 2.6 2.4
P/B ratio (x) 3.2 3.0 2.8
Dividend Yield (%) 2.0 2.2 2.5
*Bloomberg consensus estimates in reporting currency

Stock and Price Data

Country Market Cap in bn ISIN Sector Price Small Cap
Germany EUR  55.9 DE000SHL1006 Health Care EUR  49.53 No

Performance

Created with Highcharts 6.1.1Share Price (EUR)MSCI Germany (NR) (rebased)Sep '19Jan '20May '20Sep '20Jan '21May '21Sep '21Jan '22May '22203040506070

Performance in %

Since inception* YTD Last 6 months
47.00 -23.6 -13.6
*Inception date:05.07.2018

VP Bank Sustainability Score

VP Bank Sustainability Score

Very good

VP Bank Sustainability Score
VP Bank ESG score

3

ESG Score
VP Bank ESG Momentum score

4

ESG-Momentum
VP Bank Business practice score

4

Business practices
VP Bank Business activity score

3

Business activity
VP Bank SDG / Impact score

4

SDG/Impact Score